# Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer

> **NCT05601505** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 470 (estimated)

## Conditions studied

- Locally Advanced Rectal Carcinoma
- Circulating Tumor DNA

## Interventions

- **OTHER:** circulating tumor DNA

## Key facts

- **NCT ID:** NCT05601505
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-03
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-11-01
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601505, "Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05601505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*